A method for estimating vaccine-preventable pediatric influenza pneumonia hospitalizations in developing countries: Thailand as a case study

The burden of influenza in children is increasingly appreciated; some middle-income countries are considering support for influenza vaccine programs. To support decision-making, methods to estimate the potential impact of proposed programs are needed. Using Thailand as a case-study, we present a mod...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Vaccine Ročník 29; číslo 26; s. 4416 - 4421
Hlavní autoři: Dawood, Fatimah S., Fry, Alicia M., Muangchana, Charung, Sanasuttipun, Wiwan, Baggett, Henry C., Chunsuttiwat, Supamit, Maloney, Susan A., Simmerman, James Mark
Médium: Journal Article
Jazyk:angličtina
Vydáno: Kidlington Elsevier Ltd 10.06.2011
Elsevier
Elsevier Limited
Témata:
ISSN:0264-410X, 1873-2518, 1873-2518
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:The burden of influenza in children is increasingly appreciated; some middle-income countries are considering support for influenza vaccine programs. To support decision-making, methods to estimate the potential impact of proposed programs are needed. Using Thailand as a case-study, we present a model that uses surveillance data, published vaccine effectiveness estimates, and vaccination coverage assumptions to estimate the impact of influenza vaccination on pediatric influenza pneumonia hospitalizations. Approximately 56,000 influenza pneumonia hospitalizations occur annually among children aged <18 years in Thailand; 23,700 (41%) may be vaccine-preventable. Vaccination of 85% of Thai children aged 7 months–4 years might prevent 30% of all pediatric influenza pneumonia hospitalizations in Thailand.
Bibliografie:http://dx.doi.org/10.1016/j.vaccine.2011.03.099
ObjectType-Case Study-2
SourceType-Scholarly Journals-1
content type line 14
ObjectType-Feature-4
ObjectType-Report-1
ObjectType-Article-3
ObjectType-Article-1
ObjectType-Feature-2
content type line 23
ObjectType-Article-2
ObjectType-Feature-1
ISSN:0264-410X
1873-2518
1873-2518
DOI:10.1016/j.vaccine.2011.03.099